search
Back to results

Hyaluronic Acid in Acute Exacerbation of COPD - Duration Of Noninvasive Assistance (HAEC-DONA)

Primary Purpose

Chronic Obstructive Pulmonary Disease

Status
Completed
Phase
Phase 2
Locations
Italy
Study Type
Interventional
Intervention
HMW-HA
Placebo
Sponsored by
Campus Bio-Medico University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Chronic Obstructive Pulmonary Disease

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Aged 18 years of age or older
  • Admitted for respiratory failure primarily due to COPD exacerbation
  • Requiring non-invasive ventilation
  • Respiratory distress, as evidenced by moderate-to-severe dyspnea and use of accessory muscles of respiration
  • Hypercapnic respiratory failure
  • High respiratory rate

Exclusion Criteria:

  • Respiratory arrest or the need for immediate intubation
  • Upper airways obstruction
  • Facial trauma
  • Inability to cooperate

Sites / Locations

  • Università Campus Biomedico di Roma

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

HMW-HA

Placebo

Arm Description

HMW-HA (Yabro - 5 ml of saline containing 0.3% hyaluronic acid sodium salt) via nebulizer b.i.d.

5 ml of saline via nebulizer b.i.d.

Outcomes

Primary Outcome Measures

Cumulative time on NIV
Cumulative duration of NIV in hours during the enrollement

Secondary Outcome Measures

Rate of decline of time on NIV
rapidity of weaning from NIV

Full Information

First Posted
February 2, 2016
Last Updated
January 24, 2020
Sponsor
Campus Bio-Medico University
Collaborators
National Institute of Environmental Health Sciences (NIEHS)
search

1. Study Identification

Unique Protocol Identification Number
NCT02674880
Brief Title
Hyaluronic Acid in Acute Exacerbation of COPD - Duration Of Noninvasive Assistance
Acronym
HAEC-DONA
Official Title
Use of High-molecular Weight Hyaluronan in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Diseases Treated With Non-invasive Ventilation: Feasibility and Outcomes
Study Type
Interventional

2. Study Status

Record Verification Date
January 2020
Overall Recruitment Status
Completed
Study Start Date
March 2016 (Actual)
Primary Completion Date
January 2019 (Actual)
Study Completion Date
September 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Campus Bio-Medico University
Collaborators
National Institute of Environmental Health Sciences (NIEHS)

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The objective of this study is to test the effect of High Molecular Weight Hyaluronic Acid (HMW-HA) on Non Invasive Ventilation (NIV) effectiveness in patients admitted to a sub-intensive care unit for respiratory failure due to acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD).
Detailed Description
The objective of this study is to test the effect of HMW-HA on NIV effectiveness in patients admitted to a sub-intensive care unit for respiratory failure due to acute exacerbation of COPD. The design is a parallel-arm, single-blind, placebo-controlled randomized clinical trial. Eighty patients, aged eighteen years or older, admitted for respiratory failure primarily due to COPD exacerbation and requiring non-invasive ventilation will be enrolled and randomized to the study treatment (active or placebo). All patients will be treated with NIV delivered using a Hamilton C1 ventilator and medical therapy according to current guidelines (inhaled long-acting b2 agonists, inhaled long-acting anticholinergic, inhaled and systemic corticosteroids, antibiotics). Patients randomized to the active intervention group will also receive HMW-HA (Yabro® - 5 ml of saline containing 0.3% hyaluronic acid sodium salt) via nebulizer b.i.d., while patients randomized in the control group will receive a matching placebo. Patients will be treated until weaning or until NIV failure, defined as oro-tracheal intubation or death.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Obstructive Pulmonary Disease

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
41 (Actual)

8. Arms, Groups, and Interventions

Arm Title
HMW-HA
Arm Type
Experimental
Arm Description
HMW-HA (Yabro - 5 ml of saline containing 0.3% hyaluronic acid sodium salt) via nebulizer b.i.d.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
5 ml of saline via nebulizer b.i.d.
Intervention Type
Drug
Intervention Name(s)
HMW-HA
Other Intervention Name(s)
Yabro
Intervention Description
Aerolized administration b.i.d.
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
Standard therapy
Primary Outcome Measure Information:
Title
Cumulative time on NIV
Description
Cumulative duration of NIV in hours during the enrollement
Time Frame
Day 1-10
Secondary Outcome Measure Information:
Title
Rate of decline of time on NIV
Description
rapidity of weaning from NIV
Time Frame
Day 1-10
Other Pre-specified Outcome Measures:
Title
Indices of NIV efficacy over one week of treatment
Description
measures of effectiveness of ventilation in a week of treatment
Time Frame
7 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Aged 18 years of age or older Admitted for respiratory failure primarily due to COPD exacerbation Requiring non-invasive ventilation Respiratory distress, as evidenced by moderate-to-severe dyspnea and use of accessory muscles of respiration Hypercapnic respiratory failure High respiratory rate Exclusion Criteria: Respiratory arrest or the need for immediate intubation Upper airways obstruction Facial trauma Inability to cooperate
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Raffaele Antonelli Incalzi, MD
Organizational Affiliation
Università Campus Biomedico di Roma
Official's Role
Principal Investigator
Facility Information:
Facility Name
Università Campus Biomedico di Roma
City
Roma
State/Province
RM
ZIP/Postal Code
00128
Country
Italy

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
33517896
Citation
Galdi F, Pedone C, McGee CA, George M, Rice AB, Hussain SS, Vijaykumar K, Boitet ER, Tearney GJ, McGrath JA, Brown AR, Rowe SM, Incalzi RA, Garantziotis S. Inhaled high molecular weight hyaluronan ameliorates respiratory failure in acute COPD exacerbation: a pilot study. Respir Res. 2021 Feb 1;22(1):30. doi: 10.1186/s12931-020-01610-x.
Results Reference
derived

Learn more about this trial

Hyaluronic Acid in Acute Exacerbation of COPD - Duration Of Noninvasive Assistance

We'll reach out to this number within 24 hrs